GFAP and Alzheimer disease: In addition to amyloid and tau biomarkers, glial fibrillary acidic protein (GFAP) serves as a marker of astrocytic activation and neuroinflammation, processes that occur early in AD pathophysiology and may precede overt cognitive decline.8